MX2024008819A - Composiciones y metodos para reducir la oxidacion de igf-1/igfbp. - Google Patents
Composiciones y metodos para reducir la oxidacion de igf-1/igfbp.Info
- Publication number
- MX2024008819A MX2024008819A MX2024008819A MX2024008819A MX2024008819A MX 2024008819 A MX2024008819 A MX 2024008819A MX 2024008819 A MX2024008819 A MX 2024008819A MX 2024008819 A MX2024008819 A MX 2024008819A MX 2024008819 A MX2024008819 A MX 2024008819A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- igfbp
- methods
- oxidation
- igf
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 230000003647 oxidation Effects 0.000 title abstract 2
- 238000007254 oxidation reaction Methods 0.000 title abstract 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 title 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 title 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 title 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 abstract 3
- 102100037852 Insulin-like growth factor I Human genes 0.000 abstract 3
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 abstract 3
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 abstract 3
- 239000003963 antioxidant agent Substances 0.000 abstract 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 206010036590 Premature baby Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 abstract 1
- 235000019345 sodium thiosulphate Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4743—Insulin-like growth factor binding protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263300860P | 2022-01-19 | 2022-01-19 | |
| PCT/EP2023/051110 WO2023139115A1 (en) | 2022-01-19 | 2023-01-18 | Compositions and methods for reducing oxidation of igf‐1/igfbp |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008819A true MX2024008819A (es) | 2024-09-17 |
Family
ID=85036292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008819A MX2024008819A (es) | 2022-01-19 | 2023-01-18 | Composiciones y metodos para reducir la oxidacion de igf-1/igfbp. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250099541A1 (enExample) |
| EP (1) | EP4466281A1 (enExample) |
| JP (1) | JP2025502349A (enExample) |
| KR (1) | KR20240136382A (enExample) |
| CN (1) | CN118574840A (enExample) |
| AU (1) | AU2023210427A1 (enExample) |
| CA (1) | CA3242513A1 (enExample) |
| IL (1) | IL314331A (enExample) |
| MX (1) | MX2024008819A (enExample) |
| WO (1) | WO2023139115A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3005966T3 (en) * | 2020-10-19 | 2025-03-17 | Oak Hill Bio Ltd | Compositions suitable for use in neonates |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL71991A (en) | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
| AU627423B2 (en) | 1987-04-06 | 1992-08-27 | Celtrix Pharmaceuticals, Inc. | Human somatomedin carrier protein subunits and process for producing them |
| DK131988A (da) | 1988-03-11 | 1989-09-12 | Erasmus University | Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur |
| US5258287A (en) | 1988-03-22 | 1993-11-02 | Genentech, Inc. | DNA encoding and methods of production of insulin-like growth factor binding protein BP53 |
| DE3854842T2 (de) | 1988-04-12 | 1996-06-13 | Amgen Boulder Inc | Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors |
| GB8826451D0 (en) | 1988-11-11 | 1988-12-14 | Sandoz Ltd | Improvements in/relating to organic compounds |
| IL92816A0 (en) | 1988-12-22 | 1990-09-17 | Biogrowth Inc | Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides |
| AU4238493A (en) | 1992-05-08 | 1993-12-13 | Thomas Jefferson University | IGF-1 analogs |
| US5563046A (en) | 1993-08-02 | 1996-10-08 | Celtrix Pharmaceuticals, Inc. | Fusion polypeptides and proteins |
| US5789547A (en) | 1995-06-07 | 1998-08-04 | Celtrix Pharmaceuticals, Inc. | Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding |
| US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| US20110152188A1 (en) * | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
| ES3005966T3 (en) | 2020-10-19 | 2025-03-17 | Oak Hill Bio Ltd | Compositions suitable for use in neonates |
-
2023
- 2023-01-18 JP JP2024542255A patent/JP2025502349A/ja active Pending
- 2023-01-18 CA CA3242513A patent/CA3242513A1/en active Pending
- 2023-01-18 CN CN202380017851.4A patent/CN118574840A/zh active Pending
- 2023-01-18 AU AU2023210427A patent/AU2023210427A1/en active Pending
- 2023-01-18 US US18/730,442 patent/US20250099541A1/en active Pending
- 2023-01-18 IL IL314331A patent/IL314331A/en unknown
- 2023-01-18 KR KR1020247027032A patent/KR20240136382A/ko active Pending
- 2023-01-18 EP EP23701335.4A patent/EP4466281A1/en active Pending
- 2023-01-18 MX MX2024008819A patent/MX2024008819A/es unknown
- 2023-01-18 WO PCT/EP2023/051110 patent/WO2023139115A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4466281A1 (en) | 2024-11-27 |
| JP2025502349A (ja) | 2025-01-24 |
| CN118574840A (zh) | 2024-08-30 |
| CA3242513A1 (en) | 2023-07-27 |
| AU2023210427A1 (en) | 2024-08-22 |
| WO2023139115A1 (en) | 2023-07-27 |
| AU2023210427A2 (en) | 2025-01-09 |
| KR20240136382A (ko) | 2024-09-13 |
| IL314331A (en) | 2024-09-01 |
| US20250099541A1 (en) | 2025-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tsuboi et al. | Co-administration of insulin-like growth factor (IGF)-I and IGF-binding protein-1 stimulates wound healing in animal models | |
| Burton et al. | Parathyroid hormone related peptide can function as an autocrine growth factor in human renal cell carcinoma | |
| US7081240B1 (en) | Protein mixtures for wound healing | |
| Bergler et al. | Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia | |
| ES2261136T3 (es) | Composicion terapeutica de ascorbato con lisina y arginina para prevencion y tratamiento del cancer. | |
| Abad et al. | A comparative immunocytochemical study of the gastro-entero-pancreatic (GEP) endocrine system in a stomachless and a stomach-containing teleost | |
| Torricelli et al. | L-arginine and L-lysine stimulation on cultured human osteoblasts | |
| JPH06510453A (ja) | 創傷の処理のための組成物及び方法 | |
| Scharla et al. | 1, 25-Dihydroxyvitamin D3 increases secretion of insulin-like growth factor binding protein-4 (IGFBP-4) by human osteoblast-like cells in vitro and elevates IGFBP-4 serum levels in vivo | |
| Celenk et al. | Management of incus long process defects: incus interposition versus incudostapedial rebridging with bone cement | |
| PT661990E (pt) | Metodo para tratamento sistemico de condicoes catabolicas e de lesoes sistemicas em tecidos | |
| Zitelli et al. | A regional approach to reconstruction of the upper lip | |
| JPH10512235A (ja) | 骨形成の促進および骨再造形の調節のためのｉｇｆ／ｉｇｆｂｐ複合体 | |
| Hill et al. | Control of protein and matrix-molecule synthesis in isolated ovine fetal growth-plate chondrocytes by the interactions of basic fibroblast growth factor, insulin-like growth factors-I and-II, insulin and transforming growth factor-β1 | |
| Temple et al. | Effect of nutrition, diet and suture material on long term wound healing | |
| JP2006063088A (ja) | ビタミン類と無機塩類をベースにした抜毛を低減させ及び／又は毛髪の成長を促進させる組成物 | |
| MX9301387A (es) | Metodo y composicion para el tratamiento de osteoporosis. | |
| Kuwano et al. | Coexistence of intraepithelial carcinoma and glandular differentiation in esophageal squamous cell carcinoma | |
| ES2236525T3 (es) | Antarticina-nf3 para el tratamiento y re-epitelizacion. | |
| CA3242513A1 (en) | Compositions and methods for reducing oxidation of igf?1/igfbp | |
| US3257280A (en) | Gelatin and copper chelate nail bodying compositions and methods | |
| CN111214433A (zh) | 一种用于治疗妊娠纹和疤痕的组合物及其制备方法 | |
| Balk et al. | Somatomedins (insulin-like growth factors), but not growth hormone, are mitogenic for chicken heart mesenchymal cells and act synergistically with epidermal growth factor and brain fibroblast growth factor | |
| DK1069912T3 (da) | Injicerbare IGF-formuleringer, der indeholder succinat som puffermiddel | |
| MEYERS | Prophylactic antibiotics in nasal surgery |